 |
|
|
| |
VIR-2218 Plus VIR-3434 Combination Therapy Reduces Hepatitis B Virus Surface Antigen Levels In Vivo
|
| |
| |
EASL 2022 June 22-26 London
Julia Noack,1 Jonathan Gall,1a Hasan Imam,1 Yesseinia Anglero-Rodriguez,2 Vasant Jadhav,2 Michael A. Schmid,3 Anna I. Bakardjiev,1a Lisa A. Purcell,1 Christy Hebner,1 Florian A. Lempp1
1Vir Biotechnology, San Francisco, CA, USA; 2Alnylam Pharmaceuticals, Cambridge, MA, USA; 3Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
aAffiliation at time of study.
|
| |
|
|
|
|
|
